Accuray Unveils New Company Website Reflecting Industry-Leading Patient-First Cancer Treatment Innovation and Care

Sunnyvale, California (ots/PRNewswire) -

Accuray Incorporated (Nasdaq: ARAY) announced today the unveiling
of a new corporate website that reflects the company's evolution and
leadership in patient-first cancer treatment innovations. The fully
redesigned, modern site puts critical disease and treatment
information at the fingertips of website visitors, highlights the
unique features and capabilities that set the company's radiotherapy
tools-including the CyberKnife
(https://www.accuray.com/cyberknife/)®, TomoTherapy
(https://www.accuray.com/tomotherapy/)® and Radixact
(https://www.accuray.com/radixact/)® Systems-apart, and will serve as
home base for details on future breakthroughs. Check out the new site
at http://www.accuray.com.

"We take a patient-first approach to everything we do. As part of
this, we continually introduce cancer treatment breakthroughs that
help our customers improve clinical and economic outcomes. Now, our
website accurately represents this patient centricity and innovative
spirit," said Birgit Fleurent, Chief Marketing Officer at Accuray.
"We hope you'll take a moment to check out the new accuray.com and
explore the enhanced features and functionality designed to better
serve our customers, our community and everyone involved in a
patient's cancer care journey. This is the bold new face of Accuray
and we're excited to share it with you."

Take a tour of the new website here
(https://youtu.be/dwsAeVl0ldk).

The company's online home boasts a variety of new features and
enhancements that improve the user experience and expand access to
information, including:

- Clean, intuitive navigation and faster load times allow visitors to
quickly and easily find, access and understand the information they
need, including in-depth details on the company's full range of
product and software offerings
- Redesigned product pages provide visitors with interactive views of
treatment delivery, data management and treatment planning,
highlighting the precision, versatility and efficiency of all
Accuray radiation therapy tools
- A new resource center puts valuable insights-including clinical
studies, research reports, infographics, videos and fresh content
about industry trends-front and center on the website and makes
them accessible to everyone
- The Accuray Alliance section offers improved navigation, more
downloads and additional detail on the value of the company's
industry-leading service and support programs
- Dynamic and responsive design makes the site adaptable for viewing
across a variety of devices
- An enhanced treatment center locator tool helps visitors find a
treatment facility near them, anywhere in the world

Radiotherapy is a fundamental component of oncology care,[1] and
according to recent market research, the global radiotherapy market
is expected to grow from $5B in 2016 to more than $9B by 2024.[2] A
true innovator in the field, Accuray Incorporated's differentiated
product portfolio helps position the company to expand its leadership
in the marketplace.

References:

1. Gunderston LLT, Joel E. Clinical Radiation Oncology, 3rd edn.
Philadelphia, PA: Elsevier, 2011.

2. "Global Radiotherapy Market: Analysis, Companies Profiles,
Size, Share, Growth, Trends and Forecast to 2024," Research and
Markets, https://www.researchandmarkets.com/research/bmjxhg/global .

"We believe our CyberKnife, TomoTherapy and Radixact Systems have
each, individually, changed the game in radiation therapy by enabling
physicians to deliver precise, non-invasive treatment options while
minimizing side effects and helping improve quality of life for
countless patients across the globe," said Lionel Hadjadjeba, M.D.,
Senior Vice President and Chief Commercial Officer at Accuray. "The
new website shines a spotlight on what we believe differentiates our
technologies to allow them to set the stage for advancements that
will redefine the future of our industry."

Today's news follows the company's launch of two patient-facing
websites - www.cyberknife.com/ and http://www.tomotherapy.com - last
year. Built to complement http://www.accuray.com and designed
specifically for cancer patients, these two sites deliver additional
resources and information about the disease and potential treatment
options.

Important Safety Information

For Important Safety Information please refer to
https://www.accuray.com/safety-statement .

About Accuray

Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology
company that develops, manufactures, and sells precise, innovative
tumor treatment solutions that set the standard of care with the aim
of helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation therapy
and radiosurgery treatments. For more information, please visit
http://www.accuray.com or follow us on Facebook, LinkedIn, Twitter
and YouTube.

Safe Harbor Statement

Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to the
"safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements in this press release relate,
but are not limited, to clinical applications, clinical results, and
Accuray's ability to continue to penetrate the global radiation
therapy market and expand its leadership in the marketplace. These
forward-looking statements involve risks and uncertainties. If any of
these risks or uncertainties materialize, or if any of the company's
assumptions prove incorrect, actual results could differ materially
from the results expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, the company's ability to achieve widespread market
acceptance of its products, the company's ability to effectively
manage its growth, the company's ability to maintain or increase its
gross margins on product sales and services and such other risks
identified under the heading "Risk Factors" in the company's annual
report on Form 10-K, filed with the Securities and Exchange
Commission (the "SEC") on August 25, 2017, the company's quarterly
report on Form 10-Q, filed with the SEC on May 2, 2018 and as updated
periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events. The
company assumes no obligation to update forward-looking statements to
reflect actual performance or results, changes in assumptions or
changes in other factors affecting forward-looking information,
except to the extent required by applicable securities laws.
Accordingly, investors should not put undue reliance on any
forward-looking statements.

ots Originaltext: Accuray
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Sancie Nakarat
Accuray
+33-6-81-36-84-34
snakarat@accuray.com

Maely Daviles
Elan Edelman
+33(0)1-86-21-51-26
maely.daviles@elanedelman.com

Original-Content von: Accuray, übermittelt durch news aktuell